Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 1, 2024
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysisPablo Cerezuela-Fuentes, Maria Gonzalez-Cao, Teresa Puertolas, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
Nature Communications|November 19, 2022
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS<sup>Q61</sup>-mutated melanomas to targeted therapyKimberley McGrail, Paula Granado-Martínez, Rosaura Esteve-Puig, et al.
Nature Genetics|September 12, 2024
Five latent factors underlie response to immunotherapyJoseph Usset, Axel Rosendahl Huber, Maria A Andrianova, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2026
Quality and safety of research biopsies in oncology clinical trialsPaolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.
Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Communications Biology|July 11, 2020
STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammationPaula Granado-Martínez, Sara Garcia-Ortega, Elena González-Sánchez, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 1, 2024
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysisPablo Cerezuela-Fuentes, Maria Gonzalez-Cao, Teresa Puertolas, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
Nature Communications|November 19, 2022
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS<sup>Q61</sup>-mutated melanomas to targeted therapyKimberley McGrail, Paula Granado-Martínez, Rosaura Esteve-Puig, et al.
Nature Genetics|September 12, 2024
Five latent factors underlie response to immunotherapyJoseph Usset, Axel Rosendahl Huber, Maria A Andrianova, et al.
European Journal of Cancer (Oxford, England : 1990)|May 29, 2026
Quality and safety of research biopsies in oncology clinical trialsPaolo Nuciforo, Fiorella Ruiz-Pace, José Jimenez, et al.
Journal for Immunotherapy of Cancer|March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2023
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 TherapySarah A Weiss, Mario Sznol, Montaser Shaheen, et al.
Journal for Immunotherapy of Cancer|February 26, 2025
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020Paolo A Ascierto, Hao Tang, Sonia Dolfi, et al.
The Journal of Pathology. Clinical Research|April 17, 2024
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119Javier Cortes, Eric P Winer, Oleg Lipatov, et al.
Communications Biology|July 11, 2020
STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammationPaula Granado-Martínez, Sara Garcia-Ortega, Elena González-Sánchez, et al.
Pageof 8